92 related articles for article (PubMed ID: 9272484)
1. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography.
Gründer G; Yokoi F; Offord SJ; Ravert HT; Dannals RF; Salzmann JK; Szymanski S; Wilson PD; Howard DR; Wong DF
Neuropsychopharmacology; 1997 Sep; 17(3):175-85. PubMed ID: 9272484
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain.
Andrée B; Nyberg S; Ito H; Ginovart N; Brunner F; Jaquet F; Halldin C; Farde L
J Clin Psychopharmacol; 1998 Aug; 18(4):317-23. PubMed ID: 9690698
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907.
Ito H; Nyberg S; Halldin C; Lundkvist C; Farde L
J Nucl Med; 1998 Jan; 39(1):208-14. PubMed ID: 9443763
[TBL] [Abstract][Full Text] [Related]
4. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.
Kanerva H; Vilkman H; Någren K; Kilkku O; Kuoppamäki M; Syvälahti E; Hietala J
Psychopharmacology (Berl); 1999 Jul; 145(1):76-81. PubMed ID: 10445375
[TBL] [Abstract][Full Text] [Related]
5. [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography.
Lundkvist C; Halldin C; Ginovart N; Nyberg S; Swahn CG; Carr AA; Brunner F; Farde L
Life Sci; 1996; 58(10):PL 187-92. PubMed ID: 8602111
[TBL] [Abstract][Full Text] [Related]
6. Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy.
Knauer CS; Campbell JE; Galvan B; Bowman C; Osgood S; Buist S; Buchholz L; Henry B; Wong EH; Shahid M; Grimwood S
Eur J Pharmacol; 2008 Sep; 591(1-3):136-41. PubMed ID: 18593577
[TBL] [Abstract][Full Text] [Related]
7. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
[TBL] [Abstract][Full Text] [Related]
8. A practical synthesis of the serotonin 5-HT2A receptor antagonist MDL 100907, its enantiomer and their 3-phenolic derivatives as precursors for [11C]labeled PET ligands.
Ullrich T; Rice KC
Bioorg Med Chem; 2000 Oct; 8(10):2427-32. PubMed ID: 11058037
[TBL] [Abstract][Full Text] [Related]
9. PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics.
Goyer PF; Berridge MS; Morris ED; Semple WE; Compton-Toth BA; Schulz SC; Wong DF; Miraldi F; Meltzer HY
J Nucl Med; 1996 Jul; 37(7):1122-7. PubMed ID: 8965181
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the CNS penetration of a potent 5-HT2a receptor antagonist (MDL 100,907) and an active metabolite (MDL 105,725) using in vivo microdialysis sampling in the rat.
Scott DO; Heath TG
J Pharm Biomed Anal; 1998 May; 17(1):17-25. PubMed ID: 9608422
[TBL] [Abstract][Full Text] [Related]
11. Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907.
Hall H; Farde L; Halldin C; Lundkvist C; Sedvall G
Synapse; 2000 Dec; 38(4):421-31. PubMed ID: 11044889
[TBL] [Abstract][Full Text] [Related]
12. [3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain.
López-Giménez JF; Vilaró MT; Palacios JM; Mengod G
Neuropharmacology; 1998 Sep; 37(9):1147-58. PubMed ID: 9833645
[TBL] [Abstract][Full Text] [Related]
13. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.
Nordstrom AL; Mansson M; Jovanovic H; Karlsson P; Halldin C; Farde L; Vanover KE; Hacksell U; Brann MR; Davis RE; Weiner DM
Int J Neuropsychopharmacol; 2008 Mar; 11(2):163-71. PubMed ID: 17708779
[TBL] [Abstract][Full Text] [Related]
14. [3H]MDL 100,907: a novel selective 5-HT2A receptor ligand.
Johnson MP; Siegel BW; Carr AA
Naunyn Schmiedebergs Arch Pharmacol; 1996 Jul; 354(2):205-9. PubMed ID: 8857599
[TBL] [Abstract][Full Text] [Related]
15. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
Kehne JH; Baron BM; Carr AA; Chaney SF; Elands J; Feldman DJ; Frank RA; van Giersbergen PL; McCloskey TC; Johnson MP; McCarty DR; Poirot M; Senyah Y; Siegel BW; Widmaier C
J Pharmacol Exp Ther; 1996 May; 277(2):968-81. PubMed ID: 8627580
[TBL] [Abstract][Full Text] [Related]
16. Validation of a tracer kinetic model for the quantification of 5-HT(2A) receptors in human brain with [(11)C]MDL 100,907.
Hinz R; Bhagwagar Z; Cowen PJ; Cunningham VJ; Grasby PM
J Cereb Blood Flow Metab; 2007 Jan; 27(1):161-72. PubMed ID: 16685260
[TBL] [Abstract][Full Text] [Related]
17. A definite measure of occupancy exposures, seeking with non-radiolabeled in vivo 5-HT2A receptor occupancy and in vitro free fractions.
Bhyrapuneni G; Thentu JB; Palacharla VRC; Muddana N; Aleti RR; Ajjala DR; Nirogi R
J Recept Signal Transduct Res; 2018 Aug; 38(4):359-366. PubMed ID: 30481094
[TBL] [Abstract][Full Text] [Related]
18. Agonist and antagonist binding to rabbit cortical 5-HT2A receptors: opposite effects of magnesium.
Aloyo VJ; Salt GL; Hoffman ME; Harvey JA
Ann N Y Acad Sci; 1998 Dec; 861():280. PubMed ID: 9928290
[No Abstract] [Full Text] [Related]
19. Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907.
Watabe H; Channing MA; Der MG; Adams HR; Jagoda E; Herscovitch P; Eckelman WC; Carson RE
J Cereb Blood Flow Metab; 2000 Jun; 20(6):899-909. PubMed ID: 10894173
[TBL] [Abstract][Full Text] [Related]
20. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907.
López-Giménez JF; Mengod G; Palacios JM; Vilaró MT
Naunyn Schmiedebergs Arch Pharmacol; 1997 Oct; 356(4):446-54. PubMed ID: 9349630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
